

SPRAVATO® REMS

For Healthcare Setting Use Place Patient Label or Barcode Here

Patient Monitoring Form - Outpatient Use Only

INSTRUCTIONS:

This form is intended only for use by outpatient medical offices or clinics, excluding emergency departments.

- 1. Complete all required fields on this form after **every** treatment session for **all outpatients** enrolled in the SPRAVATO® REMS.
- $2. \ \, \text{Submit completed patient monitoring forms within } \underline{\textbf{7 days}}, \, \text{online at www.SPRAVATOrems.com or by fax (1-877-778-0091)}.$

* Indicates Required Field

indicates Required Field												
Patient Information (PRINT)												
First Name*: MI: Last Name*:					Birthdat	e* (MM/DD/YYYY):	Sex*: Male	☐ Female				
O a second transfer the street and							☐ Other					
Concomitant Medication												
Is the patient currently taking any of Benzodiazepines* Non-benzodiazepine sedative hy		☐ Yes ☐	☐ No☐ No	cause sedation or blo	ood press	sure changes?						
Psychostimulants*Monoamine oxidase inhibitors (M	AOIs)*		□ No □ No									
				NT)								
Healthcare Provider Conducting Patient Monitoring (PRINT) Last Name*:												
THIST INGINE .				Last Name.								
Telephone*:	phone*:					Email*:						
Healthcare Setting Informat	ion (PRI	NT)										
Healthcare Setting Name*:												
Healthcare Setting Address 1*:				Healthcare Setting Address 2:								
City*:		State*:	ZIP*:									
Patient Treatment Session	Informa	tion (Adminis	tration	and Monitoring	ı)							
Treatment Date*	Date (MM/DD/YYYY):											
Dose Administered*	☐ 56 mg ☐ 84 mg ☐ Other:				Lot Number:							
Treatment Duration*	Total timeminutes (from 1st device administration to completion of monitoring) Patient must be monitored for at least 2 hours							ing)				
REMS Evaluation Question*	If there was not a 2-hour minimum monitoring requirement, when would this patient have been ready to leave/no longer require monitoring? minutes from start of administration											
Monitoring of Vital Signs*	Vital signs were in acceptable range prior to: • administration? ☐ Yes ☐ No • treatment session completion? ☐ Yes ☐ No											
Monitoring of Blood Pressure*		Prior to administration										
Did the patient experience	Sedatio	n and/or Disso	ociatio	n								
Sedation*: ☐ Yes ☐ No				Dissociation*: ☐ Yes ☐ No								
Onset of symptoms from start of administration*				Onset of symptoms from start of administration*								
\square 1-29 mins \square 30-59 mins \square 60-89 mins \square 90-120 mins \square >120 mins				☐ 1-29 mins ☐ 30-59 mins ☐ 60-89 mins ☐ 90-120 mins ☐ >120 mins								
Resolution of symptoms within 2 hours?* ☐ Yes ☐ No				Resolution of symptoms within 2 hours?* Yes No								
Specify total time to resolution*:minutes				Specify total time to resolution*:minutes								
Medication(s) given for sedation?* ☐ Yes ☐ No				Medication(s) given for dissociation?* ☐ Yes ☐ No								
•If YES, name and dose of medication(s):				•If YES, name and dose of medication(s):								

© Janssen Pharmaceuticals, Inc. 2020 12/21

Fax: 1-877-778-0091



SPRAVATO® REMS

For Healthcare Setting Use Place Patient Label or Barcode Here

Patient Monitoring Form - Outpatient Use Only

* Indicates Required Field

Deticat Information (DDU)										
Patient Information (PRINT) First Name*:	MI: Last Name*:			Birthdate* (MM/DD/YYYY):	Sex*: Ma					
Healthcare Provider Conducting	Patie	nt Monitoring (PRIN	IT)							
First Name*:			Last Name*:							
Phone*:			Email:							
Treatment Date (MM/DD/YYYY):										
Serious Adverse Events (PRINT)										
A serious adverse event (SAE) for the Hospitalization Disability or permanent damage Death Life-threatening Important medical event defined as any event that may	е				above outcor	mes				
All non-serious adverse events or product quality complaints that are <u>not defined above</u> , should be reported to: Janssen at 1-800-JANSSEN (1-800-526-7736) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.										
Did the patient experience a serious adverse event?* ☐ Yes ☐ No If YES, describe below.										
Event resulted in the following: (check all that apply)		Event Timing	(Event Description Please list one event per ro	w)	Event Resolution				
 ☐ Hospitalization ☐ Disability or permanent damage ☐ Death ☐ Life-threatening ☐ Important Medical Event 	□в	uring treatment sessions etween treatment essions Date of Event (MM/DD/YYYY)	ons			☐ Yes ☐ No ☐ Unknown				
 ☐ Hospitalization ☐ Disability or permanent damage ☐ Death ☐ Life-threatening ☐ Important Medical Event 	□ в	uring treatment sessions Date of Event (MM/DD/YYYY)	ons			☐ Yes ☐ No ☐ Unknown				
☐ Hospitalization☐ Disability or permanent damage	□в	uring treatment sessicetween treatment	ons			☐ Yes				
☐ Death ☐ Life-threatening		Date of Event		□ No □ Unknown						
☐ Important Medical Event		(MM/DD/YYYY)								
Janssen Pharmaceuticals, Inc., Safety	Departr	ment may follow up to	obtain more info	rmation about these even	ts.					

Fax: 1-877-778-0091